DK0706799T3 - Immunkonjugater II - Google Patents

Immunkonjugater II

Info

Publication number
DK0706799T3
DK0706799T3 DK95113956T DK95113956T DK0706799T3 DK 0706799 T3 DK0706799 T3 DK 0706799T3 DK 95113956 T DK95113956 T DK 95113956T DK 95113956 T DK95113956 T DK 95113956T DK 0706799 T3 DK0706799 T3 DK 0706799T3
Authority
DK
Denmark
Prior art keywords
immunoconjugates
family
immune conjugates
interleukin
fragment
Prior art date
Application number
DK95113956T
Other languages
Danish (da)
English (en)
Inventor
Wolfgang Hoelzer
Siegfried Dr Matzku
Hoegen Ilka Dr Von
Wolfgang Dr Strittmatter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK0706799T3 publication Critical patent/DK0706799T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95113956T 1994-09-16 1995-09-06 Immunkonjugater II DK0706799T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94114572 1994-09-16

Publications (1)

Publication Number Publication Date
DK0706799T3 true DK0706799T3 (da) 2002-02-25

Family

ID=8216289

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95113956T DK0706799T3 (da) 1994-09-16 1995-09-06 Immunkonjugater II

Country Status (20)

Country Link
US (1) US5824782A (fr)
EP (1) EP0706799B1 (fr)
JP (2) JP3865802B2 (fr)
KR (1) KR100386171B1 (fr)
CN (1) CN1123185A (fr)
AT (1) ATE208633T1 (fr)
AU (1) AU702184B2 (fr)
CA (1) CA2158322C (fr)
CZ (1) CZ289641B6 (fr)
DE (1) DE69523857T2 (fr)
DK (1) DK0706799T3 (fr)
ES (1) ES2167391T3 (fr)
HU (1) HU221989B1 (fr)
NO (1) NO315976B1 (fr)
PL (1) PL182636B1 (fr)
PT (1) PT706799E (fr)
RU (1) RU2157701C2 (fr)
SK (1) SK282263B6 (fr)
UA (1) UA40611C2 (fr)
ZA (1) ZA957808B (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276488B2 (en) * 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
WO1999046392A1 (fr) * 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methodes et compositions utilisant des proteines de fusion chemokine-antigene tumoral comme vaccins anti-cancer
CN1295477A (zh) * 1998-03-31 2001-05-16 田边制药株式会社 排尿困难的预防或治疗剂
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
CN1305387A (zh) * 1998-04-17 2001-07-25 利思进药品公司 通过共同给予前列腺素抑制剂增强抗体－细胞因子融合蛋白介导的免疫应答
US6869606B1 (en) 1999-02-22 2005-03-22 Millennium Pharmaceuticals, Inc. Biotinylated-chemokine antibody complexes
WO2000078334A1 (fr) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Polypeptides chimeres antigeniques de chemokine et leurs utilisations
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
US6319675B1 (en) 1999-11-24 2001-11-20 Millennium Pharmaceuticals, Inc. Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
US7208152B2 (en) * 1999-11-24 2007-04-24 Millennium Pharmaceuticals, Inc. Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE10019157A1 (de) * 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
BR0110927A (pt) * 2000-05-19 2003-03-11 Scancell Ltd Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US7754676B2 (en) 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
WO2002022687A2 (fr) 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Proteines de fusion chimiokine virale-antigene tumoral
GB0029407D0 (en) * 2000-12-01 2001-01-17 Affitech As Product
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (fr) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
EP1383785B1 (fr) 2001-05-03 2011-03-16 Merck Patent GmbH Anticorps recombine a specificite tumorale et utilisation correspondante
EP1256354A1 (fr) * 2001-05-11 2002-11-13 Schering Corporation Methodes pour le traitement du cancer
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (fr) 2001-06-13 2016-08-02 Genmab A/S Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
JP4212921B2 (ja) * 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
WO2004035537A2 (fr) 2002-10-16 2004-04-29 Euro-Celtique S.A. Anticorps se fixant sur des polypeptides ca 125/0722p associes a des cellules et leurs procedes d'utilisation
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2004055056A1 (fr) 2002-12-17 2004-07-01 Merck Patent Gmbh Forme humanisee de l'anticorps de souris 14.18 (h14.18) se liant au gd2 et fusion de celle-ci avec il-2
EP1578801A2 (fr) * 2002-12-27 2005-09-28 Domantis Limited Anticorps a domaine unique ayant une double specificite pour un ligand et son recepteur
JP2006517970A (ja) * 2003-02-14 2006-08-03 ユニバーシティ オブ サザン カリフォルニア 癌免疫療法のための組成物及び方法
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1702069A2 (fr) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukine-12 ciblee sur la fibronectine oncofoetale
CA2560305C (fr) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Anticorps du recepteur du facteur de croissance anti-epidermique humain
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
RU2290948C1 (ru) * 2005-06-14 2007-01-10 Северо-Осетинская государственная медицинская академия Способ получения интерлейкина-8 из нейтрофилов крови доноров
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
CN101173008B (zh) * 2006-11-01 2011-06-22 复旦大学 一种双功能融合蛋白及其制备方法和应用
WO2008137066A1 (fr) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Utilisation de nanoparticules d'acide nucléique compacté dans des traitements non-viraux de maladies oculaires
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
CN101868246A (zh) * 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2009114110A1 (fr) * 2008-03-08 2009-09-17 Immungene, Inc. Immunothérapie avec molécules de fusion modifiées utilisées dans le cancer et les maladies inflammatoires
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
CA2748889A1 (fr) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions et procedes pour le transport de proteines de fusion igg-recepteur leurre a travers la barriere hemato-encephalique
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
EP2485761B1 (fr) 2009-10-09 2019-02-27 Armagen, Inc. Procédés et compositions destinés à augmenter l'activité iduronate 2-sulfatase dans le snc
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
EP3559049B1 (fr) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
WO2015143091A1 (fr) 2014-03-19 2015-09-24 Genzyme Corporation Modification de la glyco-ingéniérie de fractions de ciblage spécifique à un site
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA3205824A1 (fr) 2014-10-09 2016-04-14 Genzyme Corporation Conjugues medicament-anticorps modifies par glycane
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2017059477A1 (fr) * 2015-10-07 2017-04-13 Sangui Bio Pty. Ltd Préparation et profilage sanguins
CN117717604A (zh) 2016-07-19 2024-03-19 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
WO2019067871A2 (fr) * 2017-09-29 2019-04-04 Nantcell, Inc. Protéines antigéniques et méthodes associées
EP3898626A1 (fr) 2018-12-19 2021-10-27 Array Biopharma, Inc. Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
CN120192414A (zh) 2019-04-03 2025-06-24 建新公司 具有降低的断裂的抗αβTCR结合多肽

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (fr) * 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
CA2082160C (fr) * 1991-03-06 2003-05-06 Mary M. Bendig Anticorps monoclonaux humanises et chimeriques
CA2112473A1 (fr) * 1991-07-05 1993-01-21 Patricia A. Bacha Molecules a action elective sur les recepteurs du facteur de croissance de l'epiderme utilisees dans le traitement de l'arthrite inflammatoire
DK0586002T3 (da) * 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho

Also Published As

Publication number Publication date
UA40611C2 (uk) 2001-08-15
PL310493A1 (en) 1996-03-18
HU221989B1 (hu) 2003-03-28
HU9502711D0 (en) 1995-11-28
JP2006117684A (ja) 2006-05-11
NO315976B1 (no) 2003-11-24
ZA957808B (en) 1996-05-07
EP0706799B1 (fr) 2001-11-14
ES2167391T3 (es) 2002-05-16
ATE208633T1 (de) 2001-11-15
JP3865802B2 (ja) 2007-01-10
SK282263B6 (sk) 2001-12-03
CA2158322A1 (fr) 1996-03-17
CZ289641B6 (cs) 2002-03-13
DE69523857T2 (de) 2002-06-13
CZ237595A3 (en) 1996-04-17
CA2158322C (fr) 2009-06-16
HUT75836A (en) 1997-05-28
EP0706799A2 (fr) 1996-04-17
SK114595A3 (en) 1997-03-05
EP0706799A3 (fr) 1996-12-04
KR960010023A (ko) 1996-04-20
RU2157701C2 (ru) 2000-10-20
NO953650L (no) 1996-03-18
AU702184B2 (en) 1999-02-18
CN1123185A (zh) 1996-05-29
JPH0899901A (ja) 1996-04-16
NO953650D0 (no) 1995-09-15
KR100386171B1 (ko) 2003-08-21
DE69523857D1 (de) 2001-12-20
US5824782A (en) 1998-10-20
PL182636B1 (pl) 2002-02-28
AU3053395A (en) 1996-03-28
PT706799E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
DK0706799T3 (da) Immunkonjugater II
ATE267610T1 (de) Glykosylierte igg antikörper
EP0610201A4 (fr) Anticorps monoclonaux et chimeres diriges specifiquement contre le facteur humain de necrose de tumeurs.
FI963101A7 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
DE69520088D1 (de) Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
NO20002957D0 (no) Behandling med anti-ErbB2-antistoffer
NO940219L (no) Rekombinante antistoffer for human terapi
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
GB9603507D0 (en) Antibody variants
ATE132197T1 (de) Monoklonale antikörper
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
DE68920624D1 (de) Menschlicher monoklonaler Antikörper, Hybridoma, das ihn herstellt, und pharmazeutisches Mittel.
DK402485D0 (da) Tumorterapeutiskum og fremgangsmaade til dets fremstilling
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.
DK0561183T3 (da) Monoklonalt anti-gangliosid-antistof, fremstilling deraf og anvendelse deraf som tumorterapeutikum
EP0328578A4 (fr) Antigene identifie par mca 16-88.
FI895829A7 (fi) Ihmisen monoklonaaliset vasta-aineet rabiesvirusta vastaan
RU96123360A (ru) Способ лечения сепсиса у новорожденных
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.
ATE58173T1 (de) Monoklonale antikoerper und immunisierung damit.